Administration route |
None |
Pts |
68 |
Age |
Child, Adult, Older_Adult |
Outcome |
Percentage of Participants With Clonal Expansion of Cells With a Predominant OZ1 Insertion Site:0|Percentage of Participants With Insertional Oncogenesis:0|Number of Participants With Quantitative Marking of Gene Transfer Product in Peripheral Blood Mononuclear Cells (PBMC) Over Time: |
Adverse reactions |
0/68(All-cause mortality); 7/68(Injury, poisoning and procedural complications; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Pregnancy, puerperium and perinatal conditions; Psychiatric disorders; Respiratory, thoracic and mediastinal disorders; Vascular disorders) |
|